Fox News faces more pharma advertiser defections by Beth Snyder Bulik Thursday, March 14, 2019 After some drug advertisers dropped out last week, Fox host Jeanine Pirro's show didn't air Saturday and isn't scheduled this week.
Allergan activists call for split, sale, executive changes by Carly Helfand Thursday, March 7, 2019 After Allergan revealed a major pipeline prospect had flunked in phase 3, analysts predicted activists would ramp up pressure on execs. And they did.
When is a ph3 flop a good thing? Just ask Allergan's investors by Carly Helfand Thursday, March 7, 2019 A major Allergan pipeline candidate may have failed a pivotal trial, but investors cheered the news. The reason? They’re anticipating a company split.
What do Allergan activists really want? A new CEO, analyst says by Carly Helfand Tuesday, March 5, 2019 Activists have been pushing for a split of Allergan's CEO and chairman’s roles. But the campaign may be about more than just the split.
Another Allergan activist backs immediate split to CEO, chairman by Eric Sagonowsky Friday, March 1, 2019 Allergan has faced pressure to split Brent Saunders' CEO and chairman jobs, and now rebel investors are teaming up.
Allergan supports splitting CEO and chairman roles—just not yet by Eric Sagonowsky Tuesday, February 19, 2019 Allergan said it'll support an investor resolution to split up its CEO and chairman roles as part of its next leadership change.
Hedge funder renews call for Allergan CEO-chairman split by Eric Sagonowsky Tuesday, February 5, 2019 Unhappy with Allergan's performance and outlook, hedge fund Appaloosa once again called on the company to split up its CEO and chairman jobs.
Allergan accuses Botox competitor of pilfering production info by Eric Palmer Tuesday, February 5, 2019 Allergan is trying to blunt the launch of Botox competitor Jeuveau with allegations it was made with stolen manufacturing trade secrets.
Evolus' Botox competitor is here. Will it dent Allergan's sales? by Carly Helfand Monday, February 4, 2019 The moment Allergan has been dreading has arrived. Evolus has snagged its OK for a rival to Allergan’s lead moneymaker, Botox.
